- CA$12.69m
- CA$16.05m
Brief: Aspire Health Science Files Supplemental Motion For Expedited Hearing In Lawsuit Against Hemostemix Inc. And Suspends Patient Recruitment For Hemostemix Cli Phase 2 Clinical Trial
Brief: Aspire Health Sciences Says On Jan 28, 2020, Initiated Legal Proceeding Against Hemostemix Inc
Brief: Hemostemix Announces Private Placement
Brief: Hemostemix Announces Corporate Update
Brief: Hemostemix Announces Appointment Of Director
Brief: Hemostemix Announces Resignation Of Don Friesen From Board, Effective Nov. 21
Brief: Hemostemix Says Kyle Makofka Has Resigned As CEO
Brief: Hemostemix Announces Commencement Of Arbitration
Brief: Hemostemix Announces $2 Million Loan Facility
Brief: Hemostemix Announces Financing Update And Interim CFO Appointment
Brief: Hemostemix Announces Resignation Of CFO
Brief: Hemostemix Announces Convertible Debenture Financing
Brief: Hemostemix Announces Enrollment Milestone In The Acp-01 Phase Ii Critical Limb Ischemia Clinical Trial
Brief: Hemostemix Announces Appointment Of Experienced Chief Medical Officer & President
Brief: Hemostemix Announces Uc Davis Health Added As A Trial Site For Phase Ii Clinical Trial
Brief: Hemostemix Announces Submission Of Orphan Drug Designation Application To The FDA
Brief: Hemostemix Announces Milestone Achieved With First 3 U.S. Trial Sites For Phase II Clinical Trial Open For Patient Enrollment
Brief: Hemostemix Announces Departure Of David Berman As CFO
Brief: Hemostemix Announces U.S. FDA Clinical Trial Approval